Order Article Reprints

Ma Y, Sender S, Sekora A, Kong W, Bauer P, Ameziane N, Al-Ali R, Krake S, Radefeldt M, Weiss FU, et al. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences. 2022; 23(8):4295. https://doi.org/10.3390/ijms23084295

Ma, Yixuan, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Ruslan Al-Ali, Susann Krake, Mandy Radefeldt, Frank Ulrich Weiss, and et al. 2022. "The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines" International Journal of Molecular Sciences 23, no. 8: 4295. https://doi.org/10.3390/ijms23084295

Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Al-Ali, R., Krake, S., Radefeldt, M., Weiss, F. U., Lerch, M. M., Parveen, A., Zechner, D., Junghanss, C., & Murua Escobar, H. (2022). The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences, 23(8), 4295. https://doi.org/10.3390/ijms23084295